KalVista stock price target lowered to $36 by BofA on Ekterly launch data

KalVista Pharmaceuticals (KALV) reported robust initial commercial success for its new hereditary angioedema treatment, Ekterly, with 460 patient start forms and strong prescriber adoption, contributing to a Q1 FY2026 revenue beat of $1.4 million against a $951,670 forecast. While BofA Securities slightly lowered its price target to $36.00, it maintained a Buy rating, acknowledging the product's momentum and projecting significant Ekterly revenue growth to $35.7 million for FY2026. Despite rapid cash burn, the company maintains strong liquidity, and the stock's 81.7% year-to-date return reflects investor optimism, though it appears slightly overvalued by some metrics.

Analysis

KalVista Pharmaceuticals (KALV) is demonstrating strong initial commercial traction for its new hereditary angioedema (HAE) treatment, Ekterly, following its recent launch. The company reported 460 patient start forms and activation of 253 unique prescribers, with 38% already initiating treatment for multiple patients, indicating robust early adoption. This momentum translated into a significant top-line beat for fiscal Q1 2026, with net revenue of $1.4 million surpassing consensus forecasts of $951,670. In response, BofA Securities maintained its Buy rating while making a minor downward price target revision to $36.00 from $37.00, signaling a continued positive outlook tempered by a need to monitor the rollout. BofA projects Ekterly fiscal year 2026 revenues to reach $35.7 million. From a financial health perspective, the company exhibits a strong liquidity position with a current ratio of 5.35, but this is counterbalanced by a rapid cash burn rate typical of a commercial-stage biotech. Despite the stock's powerful 81.7% year-to-date return, which has led to suggestions of it being slightly overvalued, the analyst consensus remains highly bullish.

Key Decisions for Investors

• Given the stock's 81.7% year-to-date appreciation and potential overvaluation, investors should consider the strong execution risk already priced in, making entry points a key consideration.
• Monitor upcoming quarterly reports for key launch metrics beyond initial starts, specifically the conversion rate to paid prescriptions, patient retention, and the status of payor coverage, as these will be critical determinants of Ekterly's long-term revenue trajectory.
• The high cash burn rate is a primary risk factor; investors must scrutinize future cash flow statements to assess the company's runway to profitability and the potential need for future dilutive financing.